Nuvectis Pharma, Inc. (NVCT) Stock Analysis & Investment Frameworks
Nuvectis Pharma, Inc. (NVCT) stock analysis on Invetso. Review Nuvectis Pharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Nuvectis Pharma, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Nuvectis Pharma, Inc. Key Financial Metrics
- Market Cap: $675.73M
- Revenue: $N/A
- ROE: -169.47%
- ROIC: -317.86%
- Dividend Yield: N/A
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.